Home
overview

SMi is delighted to announce the return of their 7th annual Orphan Drugs and Rare Diseases conference to London on the 18th -19th October 2017!

 

With the global Orphan Drug market expected to grow to $127 billion by 2018*, and another Rare Disease Day just having passed, there is a constantly growing awareness and interest for this industry, enabling more research to make a difference in patients’ lives. SMi’s Orphan Drugs and Rare Diseases conference will once again bring together some of the leading senior industry professionals to network, learn, and discuss current issues in the rare disease industry.

 

Despite the recent growth in the orphan drug market, the way to having orphan drugs approved is still long and includes many challenges to overcome, such as regulatory and sustainability. The 7th annual Orphan Drugs and Rare Diseases conference will help connect industry professionals internationally, ensuring there is a great networking and learning opportunity to share knowledge of research, developments and issues. With topics being discussed such as Cell and Gene Therapy; Patient Recruitment and Patient-centric Research; Clinical Development, Regulatory Guidelines; Strategic Partnerships; Pricing and Reimbursement; and many more, this year's conference promises to be the perfect platform to exchange knowledge and network with your peers!

 

*Source: http://bit.ly/2mJZLJa

Join the Orphan Drugs and Rare Diseases community this year in October to keep up to date with the industry and to learn from our expert speaker panel, bringing you important new case studies and reports on this year’s relevant topics.

 

  • Discussing strategic win-win collaborations to help accelerate rare disease clinical drug development, and improve relationships between drug developers and patients to consider both parties’ interests
  • Hear more about how patient engagement by integrating the patient perspective into the drug development process through patient advocacy, patient-centric research and patient groups
  • Learn about how the regulatory landscape for drug approvals is different between countries, and why it is important to keep informed about the regulations and guidelines of each region
  • Gain knowledge of different rare diseases and their unique challenges, as well as how treatment methods can be transferred to other rare diseases
  • Introducing cell and gene therapies to rare disease treatment - learn how gene therapy methods can improve the treatment of rare diseases and why it is becoming more commercially successful

Previous attendees included:

 

Abeona Therapeutics; ADB Medical; Agency for Medicinal Products and Medical Devices of the Republic of Slovenia; Akcea Therapeutics; AKU Society; Alexion Pharma International Intl; Alexion Pharma International Sàrl; Alexion Pharma UK Ltd; Alexion Pharmaceuticals, Inc.; Apex Healthcare Consulting Limited; Birmingham Children's Hospital; Boehringer Mannheim GmbH; Cello Health Insight - London; Chiesi Farmaceutici SpA; Chiesi Ltd; Clarivate Analytics; Clinical Network Services (UK) Ltd; ClinTec International Ltd; Cydan; Debio Pharm S A; Diamond Pharma Services; Diamond PV Services; Dorphan; Findacure Development; Findacure; Genethon; Genetic Alliance; Grifols Deutschland; Grunenthal GmbH; GSK; GW Pharmaceuticals; Healx; I.D.E.A. Ltd; ICON Clinical Research; INC Research; Infusion Pharma Consulting LLC; Institute of Pharmaceutical Research & Technology (IFET SA); Loulou Foundation; Merck Serono; Mereo BioPharma Group Limited; MHRA; National Institute for Health and Care Excellence; NDA Regualtory Science Ltd; Newcastle University; Nicole Reichman; nspm UK ltd; Orphazyme ApS; Otsuka Europe Development and Commercialisation; Otsuka Pharmaceutical Europe Ltd; Personalize My Medicine; Pfizer Group; Premier Research; Proceutica; Prometic Pharma SMT; PSR Group B.V.; PSR Orphan Experts; Quintiles; Raglan Capital; Rare Base Ltd; Rare Disease UK; RBV Capital; RJW & Partners Ltd; Roche Products; Roche; Russian Respiratory Society; Shire Pharmaceuticals Limited; Society for Mucopolysaccharide Diseases; Summit Therapeutics; Swedish Orphan Biovitrum (SOBI) AB; Taylor & Francis Group; Taylor & Francis; The Birmingham Childrens Hospital; The Medical Research Network; The Ultra Rare Diseases Disorder & Disabilities Foundation; Thomson Reuters; Tikomed; University College London; URB Pharma; Vanda Pharmaceuticals; Zogenix Inc

Abeona Therapeutics ; ADB Medical ; Akcea Therapeutics; AKU Society; Alexion Pharma International Sàrl; Alexion Pharma UK Ltd; Alexion Pharmaceuticals, Inc.; Birmingham Children's Hospital; Boehringer Mannheim GmbH; Chiesi Farmaceutici SpA; Chiesi Ltd; Clarivate Analytics; Clinical Network Services (UK) Ltd; ClinTec International Ltd; Cydan; Diamond Pharma Services; Diamond PV Services; Findacure; Healx; INC Research; Institute of Pharmaceutical Research & Technology (IFET SA); Mereo BioPharma Group Limited; MHRA; National Institute for Health and Care Excellence; Nicole Reichman ; nspm UK ltd; Personalize My Medicine; Premier Research; Proceutica; Prometic Pharma SMT; PSR Orphan Experts; Quintiles; Rare Base Ltd; RBV Capital; RJW & Partners Ltd; Shire Pharmaceuticals Limited; Summit Therapeutics ; Taylor & Francis; URB Pharma; Vanda Pharmaceuticals;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

9:10 Case study: Lucerastat for Fabry Disease

Olivier Morand

Olivier Morand, Clinical Science Program Head, Actelion Pharmaceuticals
View Bio

  • Lucerastat as substrate reduction therapy for Fabry disease
  • Pivotal clinical study: putting the drug and the disease in context
  • One disease but different development paths
  • The role of patient groups
  • 9:50 Developing new therapies for rare diseases: beyond CF

    Stuart Hughes

    Stuart Hughes, Director, Head of Pharmacology, Vertex Pharmaceuticals
    View Bio

  • What are the key attributes of cystic fibrosis (CF) that have contributed to a successful drug discovery story?
  • Which other diseases have attributes similar to CF and how can we most effectively deliver therapies for these diseases?
  • How should we tackle diseases where there are gaps in the understanding of causal human biology?
  • What other novel ways can we utilise to address rare diseases?
  • 10:30 Morning Coffee

    11:00 Highlighting Duchenne muscular dystrophy (‘DMD’)

    Richard Pye

    Richard Pye, Senior Director, Corporate Affairs, Summit Therapeutics
    View Bio

  • About DMD
  • Emerging treatment approaches
  • Disease modifying and symptomatic treatments
  • 11:40 Developing a state of art telemedicine rare disease service

    Kay Parkinson

    Kay Parkinson, CEO, Cambridge Rare Disease Network (CRDN)
    View Bio

  • Need for rare disease patients to have access to experts
  • Patients use technology, mobile phones, tablets, laptops
  • Travel can be costly and difficult
  • Home support is vital for complex, multi symptom diseases
  • 12:20 Networking Lunch

    13:30 Improving the efficacy and safety profile of biologic therapeutic candidates for orphan and rare diseases by addressing product immunogenicity

    Kei  Kishimoto

    Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences
    View Bio

  • Immunogenicity is a common cause of treatment failure and hypersensitivity reactions with biologic therapies, particularly for enzyme therapies and gene therapies for orphan and rare diseases
  • We have developed technology to induce antigen-specific immune tolerance to biologic therapies
  • I will present case studies from our lead clinical program in severe refractory gout and preclinical program in gene therapy
  • 14:10 Developing the 1st Rare Disease Centre for Children in the World

    Larissa Kerecuk

    Larissa Kerecuk, Rare Disease Lead, Consultant Paediatric Nephrologist, Birmingham Children's Hospital
    View Bio

  • Challenges of Rare Diseases faced by people affected by rare diseases & co-design of centre with children & families
  • 100K Genome
  • Research and collaboration vital for rare diseases progress
  • Patient History – A Patient Speaks
  • 14:50 Afternoon Tea

    15:20 Challenges, Opportunities and Treatment of Rare Diseases

    Olaf Ritzeler

    Olaf Ritzeler, External Innovation Lead, Sanofi
    View Bio

  • Challenges of rare diseases
  • Decision matrix to choose a rare disease
  • How common disease can profit from work on rare monogentic disease
  • 16:00 Novel Approaches for the Genetic Therapy of Rare Diseases

    Richard Harbottle

    Richard Harbottle, Group Leader, DNA Vector Research, German Cancer Research Centre (DKFZ)
    View Bio

  • Progress and Successes of Gene Therapy
  • Development of Next Generation Gene Therapy Vectors
  • Gene Therapy for Rare Disease
  • Alternatives to Viruses - Non-Viral DNA Vectors for Gene Therapy
  • 16:40 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    9:10 Global Orphan Drug Regulatory Strategy

    Aaron Barzey

    Aaron Barzey, CEO, ADB Medical

  • Global orphan drug regulations
  • Joint FDA-EMA submissions
  • Impact of Brexit on the industry

  • 9:50 DevelopAKUre: Collaborating with patient groups to increase patient recruitment and retention

    Oliver Timmis

    Oliver Timmis, CEO, AKU Society
    View Bio

  • DevelopAKUre is the first truly patient-led clinical trial
  • Patient recruitment and retention led by a patient group
  • DevelopAKUre recruited 50% of a EU patient population in 9 months
  • DevelopAKUre maintains a 95% retention rate
  • 10:30 Morning Coffee

    11:00 Customer centric model to ensure successful delivery of rare disease medicines to market

    Hsin Loke

    Hsin Loke, Director of Strategy, Operations and Finance, Rare Diseases Unit, GlaxoSmithKline
    View Bio

  • The industry context is evolving rapidly such that our customers are no longer just the HCPs - patients and their carers are experts in their disease areas
  • We realised the need to improve our engagement with all our customers: patients, HCPs and payers
  • In order to meet the needs of our customers, we need to rapidly evolve and expand existing capabilities
  • 11:40 Patient's View of the Clinical Trial Process and Patient Registries

    Angela  Stringer

    Angela Stringer, Advocate & DMD Registry Curator, Action Duchenne
    View Bio

  • Clinical Trial Selection
  • Patient Perspective
  • The UK DMD Registry
  • 12:20 Networking Lunch

    13:30 Access to reimbursed treatment for ultra-rare diseases using an MAA – A Patient Perspective

    Christine Lavery

    Christine Lavery, Group Chief Executive, MPS Society
    View Bio

  • Make access to highly specialised technologies for ultra-rare diseases fair – before MAA
  • The MAA process
  • The Challenges
  • What have we learnt from the MAA for MPSIVA 1 year on
  • 14:10 Experience with an orphan product approved under exceptional circumstance

    Nadia Assenova

    Nadia Assenova, Senior Director Regulatory Affairs, EMEA, Alexion Pharma GmbH
    View Bio

  • Review of initial MAA timelines
  • Aspects of decision making on exceptional vs. conditional
  • Post-approval life cycle experience
  • Post-approval measures and specific obligations
  • 14:50 Afternoon Tea

    15:20 Repurposing Disulfiram + Copper to Treat Adult and Pediatric Brain Tumors

    Stephen Marcus

    Stephen Marcus, CEO, Cantex Pharmaceuticals
    View Bio

  • Unique oral formulation required for clinical activity
  • Well-tolerated, without bone marrow suppression
  • Inhibits DNA-repair enzyme MGMT and enhances the effects of DNA alkylating agents (e.g. Temozolomide) and radiation
  • Highly cytotoxic to glioblastoma and medulloblastoma cells
  • Readily crosses the blood-brain barrier
  • Orphan drug designation granted for glioblastoma
  • Phase II clinical trial in recurrent glioblastoma is in progress
  • 16:00 Drug Repurposing for Rare Diseases

    Rick Thompson

    Rick Thompson, Head of Research, Findacure
    View Bio

  • An introduction to drug repurposing in the rare disease space, and the novel techniques being used to identify repurposing opportunities
  • A summary of Findacure’s work in developing a new financial model to fund generic drug repurposing using social finance – the Rare Disease Drug Repurposing Social Impact Bond (RDDR SIB)
  • The RDDR SIB uses NHS savings to reimburse research costs, I will review our health economic research to prove the model’s viability
  • A summary of the results of our global open call for rare disease repurposing ideas
  • 16:40 Chairman’s Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    Kei  Kishimoto

    Kei Kishimoto

    Chief Scientific Officer, Selecta Biosciences
    Nadia Assenova

    Nadia Assenova

    Senior Director Regulatory Affairs, EMEA, Alexion Pharma GmbH
    Richard Pye

    Richard Pye

    Senior Director, Corporate Affairs, Summit Therapeutics
    Stuart Hughes

    Stuart Hughes

    Director, Head of Pharmacology, Vertex Pharmaceuticals

    Aaron Barzey

    CEO, ADB Medical
    Aaron Barzey

    Angela Stringer

    Advocate & DMD Registry Curator, Action Duchenne
    Angela  Stringer

    I am a patient advocate for Action Duchenne and curator of the UK Duchenne Muscular Dystrophy Registry.

    I had never heard of Duchenne Muscular Dystrophy until my son was diagnosed at the age of 3. At that time I felt compelled to engage with organisations to help my family and became a trustee for the Duchenne Family Support Group. As advocate and curator I speak, on a daily basis, to families affected by Duchenne and all stakeholders in the R&D arena. I am also a graduate of EUPATI (European Patients Academy for Therapeutic Innovation), gaining extra skills as an ‘expert patient’.

    Christine Lavery

    Group Chief Executive, MPS Society
    Christine Lavery

    Christine Lavery MBE, was appointed Chief Executive of the Society for Mucopolysaccharide and Related Diseases (MPS) in 1993, now employing 22 members of staff, managing a substantial research budget and a unique UK-wide advocacy service providing needs led support to nearly 1300 sufferers, their families and professionals in areas of home adaptations, special educational needs, access to new therapies, respite care, palliative care and pre- and post-bereavement support. Christine has served on the Department of Health Advisory Board on Genetic Testing and is currently a patient representative on the NHS England LSD Specialised Commissioning Advisory Group.

    Hsin Loke

    Director of Strategy, Operations and Finance, Rare Diseases Unit, GlaxoSmithKline
    Hsin Loke

    Hsin Loke is the Director of Strategy, Operations and Finance for the Rare Diseases Unit at GSK, where for the past 2 years, she has led reshaping of the Unit’s strategy and is driving operational delivery. Previously, Hsin has held different positions across GSK, including leading operations in the Biopharmaceutical platform unit, leading strategic projects for GSK R&D as part of the R&D strategy team, and also various finance roles. Separately, Hsin is a Trustee for BookTrust, UK’s largest reading charity. Prior to qualifying as a Chartered Accountant with PwC, Hsin read Biology and completed her PhD in Immunology at Oxford University.

    Janet Tuberville-Greenley

    Roald Dahl Rare Disease Transition Sister, Birmingham Children's Hospital
    Janet Tuberville-Greenley

    Rare Diseases Challenges and Opportunities Workshop Leader

    Kay Parkinson

    CEO, Cambridge Rare Disease Network (CRDN)
    Kay Parkinson

    Kay Parkinson was the mother of two children who were diagnosed with the ultra rare disease Alström Syndrome when they were aged 18 & 15, having had four previous mis-diagnosis. Both children died following heart and heart/kidney transplantations aged 25 and 29 respectively. They received little support or understanding of their rare condition.
    Kay qualified as a lawyer in 1996 as a mature student, specialising in charity law. In 1998 she founded the charity Alström Syndrome UK (ASUK). Kay served as their founder/ CEO for 15 years. In 2007 she fought the DOH to gain funding from the NHS Highly Specialised Services for the charity, she held the only UK database on affected families which she had collected since 1998. Kay stepped down in 2013 after ASUK was awarded EURORDIS Patient Organisation of the Year, to start up Alström Europe (AS EU) charity, where she still serves as a Director. In 2015 Kay joined the steering group of Cambridge Rare Disease Network as she believes all rare diseases need to work together for better diagnosis, treatments, services and a much needed higher public profile.
    From September 2015 Kay has formally set up and structured Cambridge Rare Disease Network (CRDN) as their CEO. She is enjoying the challenge of working with a novel multi-stakeholder organisation and hopes to form closer links between the Cambridge “Cluster”, the largest biotech’s in Europe, the Cambridge University and people affected by rare diseases. Kay was awarded the “Champion of Hope” award 2017 by Genetic Disorders UK for the setting up of Alstrom Syndrome Europe.

    Kei Kishimoto

    Chief Scientific Officer, Selecta Biosciences
    Kei  Kishimoto

    Dr. Kishimoto is the Chief Scientific Officer of Selecta Biosciences, a biotechnology company developing synthetic vaccines based on a novel self-assembling nanoparticle technology. Prior to joining Selecta, Dr. Kishimoto was Vice President of Research at Momenta Pharmaceuticals where he led multidisciplinary teams in inflammation, oncology, and cardiovascular disease. Previously he was Senior Director of Inflammation Research at Millennium Pharmaceuticals, where he provided the scientific leadership for four programs in clinical development, and an Associate Director of Immunology at Boehringer Ingelheim. Dr. Kishimoto received his doctoral degree in Immunology from Harvard University and his post-doctoral training at Stanford University.

    Larissa Kerecuk

    Rare Disease Lead, Consultant Paediatric Nephrologist, Birmingham Children's Hospital
    Larissa Kerecuk

    Dr Larissa Kerecuk is very proud to be the Rare Disease Lead at Birmingham Children’s Hospital where she is developing the first Children’s Rare Disease Centre in the UK. This centre will provide a better integrated holistic care for children, young people and families affected by rare diseases as well as increasing access to research and new treatments.
    Larissa is the lead for the 100 000 Genome Project at Birmingham Children’s Hospital, the lead recruiter in the West Midlands, which will provide a diagnosis and personalised approach to many yet undiagnosed children.
    As Consultant Paediatric Nephrologist, Larissa specialises in treating children with kidney diseases including those on dialysis, which requires a holistic approach. Larissa is also Renal Research and Transition Lead and places great importance in integrating care for all patients. Larissa is the founder and coordinator of the Autosomal Recessive Polycystic Kidney Disease Rare Disease Group in the UK and has established international collaborations with the US and Europe. Larissa also developed the Human Factors Course to improve patient safety. More recently Larissa has been appointed as the NIHR Clinical Specialty Lead for Paediatrics in the West Midlands and her vision is for research to become an integral part of everyday NHS care.

    Nadia Assenova

    Senior Director Regulatory Affairs, EMEA, Alexion Pharma GmbH
    Nadia Assenova

    Nadia Assenova MPharm, MBA, MSc is Senior Director, Regulatory Affairs EMEA region, at Alexion in Zurich. She has over 15 years of experience in global regulatory affairs. She joined Alexion in 2015 focusing on the registration of Orphan Medical products across the globe. Throughout her career, Nadia has been directly involved in multiple regulatory submissions, most recently focusing on development of new indications in ultra-rare diseases and regulatroy strategy for the metabolic products within the Alexion pipeline. Nadia received her Pharmacy MSc degree from the University of Medicine in Sofia (Bulgaria). She also holds an MBA from the University of Strathclyde (UK) and M.Sc. in Health Policy from Imperial College London (UK).

    Olaf Ritzeler

    External Innovation Lead, Sanofi
    Olaf Ritzeler

    Dr. Olaf Ritzeler scouts and evaluates external R&D opportunities in Europe at all development stages with a therapeutic focus on rare diseases. He is working in a global, transversal team to which he brings his strong expertise on drug discovery and development. The research teams led by him have delivered one phase IIb-, two phase I-, five preclinical- and six lead candidates. His contribution to Sanofi’s drug-pipeline was awarded by the “Meilenstein Preis” and “Drug Hunter Award” for outstanding efforts and key contribution to drug innovation and approval.

    Oliver Timmis

    CEO, AKU Society
    Oliver Timmis

    Oliver Timmis is CEO of the AKU Society, a patient group helping those diagnosed with a rare disease called alkaptonuria (AKU). Oliver had partnered with NHS National Specialised Services to fund the National AKU Centre in Liverpool, UK, and secured funding from the European Commission for international phase III clinical trials called DevelopAKUre.

    Olivier Morand

    Clinical Science Program Head, Actelion Pharmaceuticals
    Olivier Morand

    Olivier Morand is Senior Director, Clinical Science Program Head, at Actelion Pharmaceuticals Ltd, Allschwil, Switzerland. His focus is on new therapies for rare metabolic diseases. While at Actelion he was also leading the Life Cycle team that successfully ran the Zavesca® program for type 1 Gaucher disease and Niemann-Pick type C disease. Previously he held research positions in Drug Discovery at Roche in Basel, Switzerland and at Merck & Co. in Rahway, NJ (USA). He developed his know-how in several academic institutions such as the University of Wisconsin, Madison, the Hadassah School of Medicine, Jerusalem, and the Mount Sinai School of Medicine, New York. He holds two PhDs in Biochemistry and Nutrition (University of Paris).

    Richard Harbottle

    Group Leader, DNA Vector Research, German Cancer Research Centre (DKFZ)
    Richard Harbottle

    Dr Richard Harbottle undertook his PhD and post-doctoral training in a Gene Therapy lab at Imperial College London where he worked on developing non-viral methods for introducing DNA into cells. He is currently the Research Group Leader of the DNA Vector Laboratory at the German Cancer Research Centre (DKFZ) in Heidelberg. His lab is now focused on the generation and application of novel, next-generation DNA vectors for gene therapy and for the safe and persistent genetic modification of cells. These DNA vectors provide therapeutic transgene expression without the use of potentially toxic viral components or the risk of insertional mutagenesis.

    Richard Pye

    Senior Director, Corporate Affairs, Summit Therapeutics
    Richard Pye

    Dr Richard Pye joined Summit in 2004 as a Senior Scientist and was involved in the formative development of the Company including being involved in the discovery of ezutromid for the treatment of Duchenne muscular dystrophy. He subsequently moved into the corporate side of the business and currently has responsibility for corporate affairs, communications and investor relations. He has a broad range of experiences and skills having been involved in a various corporate development activities including raising equity financing from the capital markets and securing funding from not-for-profit organisations and Summit’s initial public offering on NASDAQ that completed in 2015. Richard holds a PhD in Organic Chemistry and prior to joining Summit was a Post-Doctoral Research Associate at The University of Oxford.

    Rick Thompson

    Head of Research, Findacure
    Rick Thompson

    Dr Rick Thompson joined Findacure in 2015, after completing his PhD in Evolutionary Biology at the University of Cambridge. As Head of Research, he is responsible for their scientific projects, with the aim of developing a socially financed drug repurposing programme – Findacure’s rare disease drug repurposing social impact bond (RDDR SIB). Rick has designed and completed a proof of concept study to demonstrate the feasibility of the RDDR SIB to the NHS, investors, industry, and patient groups. He also works to encourage industry engagement with rare disease patient groups, promoting an open and collaborative approach to rare disease research.

    Stephen Marcus

    CEO, Cantex Pharmaceuticals
    Stephen Marcus

    Stephen G. Marcus, M.D., is a medical oncologist and pharmaceutical executive who has led the development of several profitable pharmaceutical and biotechnology products. Dr. Marcus led the development of Betaseron, the first effective treatment for multiple sclerosis, and was instrumental in the development of Intron A, Temodar, Fludara, and brand-equivalent Paclitaxel.

    Stuart Hughes

    Director, Head of Pharmacology, Vertex Pharmaceuticals
    Stuart Hughes

    Stuart Hughes is Director and Head of Pharmacology at Vertex Pharmaceuticals Europe Ltd. Following the award of a PhD in Cellular and Molecular Neuroscience from Cardiff University in 1999 he spent several years as a postdoctoral scientist studying the mechanisms that underlie a host of physiological and pathological brain rhythms. In 2006 he was awarded a Wellcome Research Fellowship to continue this work and made important contributions to the understanding of the cellular events that lead to the slow waves of deep sleep as well as the neural mechanisms that shape the so-called alpha rhythm of relaxed wakefulness. In 2008, he took up a position as a group leader in CNS research at Eli Lilly and Company, pursuing a range of ion channel targets for treating a variety of neurological and psychiatric disorders. In 2013, he moved to Vertex Pharmaceuticals to lead the UK in vivo pharmacology group where his main areas of focus have been on orphan diseases, cancer and neurodegeneration.

    Workshops

    Rare Diseases Challenges and Opportunities
    Workshop

    Rare Diseases Challenges and Opportunities

    Holiday Inn Kensington Forum
    17th October 2017
    London, United Kingdom

    VENUE

    Holiday Inn Kensington Forum

    97 Cromwell Road , London, United Kingdom

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

    HOTEL BOOKING FORM

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Holiday Inn Kensington Forum

    97 Cromwell Road
    London SW7 4DN
    United Kingdom

    Holiday Inn Kensington Forum

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.